• Manufacturing

Gene therapy: the challenge and the opportunity

By Annie Zeng Gene therapy is an experimental and therapeutic technique involving the engineering of genes with the hope to cure disease at its root cause. This has become an increasingly buoyant area for investment and although still at an early phase of development, there have been recent approvals of clinical and commercial gene therapies for use in humans.

Evonetix collaborates with imec to scale-up chip-based technology production for third generation DNA synthesis platform

Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has partnered with imec to increase production of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon chips, enabling the platform to be manufactured at a commercial scale.

Impact of the ATTC Network after 18 months of operation

Just 18 months ago, the Advanced Therapy Treatment Centre (ATTC) network was set up through funding from the UK Research and Innovation Industrial Strategy Challenge Fund.

£1.2m investment to reinforce Stevenage Campus as world class cell and gene therapy hub

Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster. The £1.2m Local Growth Fund investment will provide much-needed temporary accommodation for growing cell and gene therapy companies, strengthening the UK’s sectorial advantage and Hertfordshire’s position within the Oxford-London-Cambridge golden research triangle.

Evonetix expands facilities and relocates to central Cambridge, UK

Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has moved to Coldham’s Business Park, Cambridge, UK. The new facility will enable the continued growth of the Company as it continues in its mission to develop a desktop DNA synthesis platform based on its proprietary silicon chip.

Enterprise Therapeutics awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator

Brighton, UK, 15 October 2019: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has been awarded up to £5.7M ($7M) funding under the Therapeutics Development Award programme from the Cystic Fibrosis Foundation.

MedAnnex begins cell line development at FUJIFILM Diosynth

Edinburgh-based biotechnology company MedAnnex today announced that cell line development for the generation of its anti-Annexin A1 antibodies is under way, at FUJIFILM Diosynth Biotechnologies’ (Fujifilm) Billingham, UK site.

Cellexus go global with new distribution network

Biotech company, Cellexus International Ltd, have increased their distributor network to bring their CellMaker bioreactor range to a global market.

Cobra Biologics and Symbiosis Complete £4.8m Viral Vector Supply Chain Collaboration

Developing world-leading capabilities in drug substance and drug product viral vector production for gene and immunotherapy.

Oxford Biomedica named as winner of The Oxford Science Park Innovation Award 2019

Leading gene therapy manufacturer recognised as part of Oxfordshire Business Awards Oxford, UK, June 18 2019 - Its work on life-changing treatments for serious diseases has earned Oxford Biomedica, a leading gene and cell therapy group, The Oxford Science Park Innovation Award 2019.